Teldar Paper retweeted
$ABVX Scorpion called Abivax a fraud. To believe that requires the reader to completely dismiss the very large clinical dataset and/or believe this is the greatest conspiracy in the history of medicine by an order of magnitude. Show the falsified records. Show the cancer excess at the dose you’re attacking. Explain why blinded readers saw healthier colons on both scopes and biopsies. The evidence Scorpion made public falls well short of its headline, and they themselves tell you that they've already covered their short position by the time you read through the report. scorpioncapital.com/
Start with 50 mg dose.
In June, we estimated 0.59 cancers per 100 patient-years at 50 mg, excluding non-melanoma skin cancer. We kept the doses separate because 50 mg was the dose under scrutiny. Abivax’s July deck put the updated number at 0.64 across 944 patient-years at 50 mg, within its historical ulcerative colitis range of 0.30–0.70. Non-melanoma skin cancer also came in at 0.64, below the company’s 0.70–1.40 benchmark. Those are the 50 mg numbers. teapaw.org/deathtouch2k/status/20… · ir.abivax.com/static-files/b…
Yes, the narrower Phase 3 maintenance analysis came in higher. Four cases over 438 patient-years gave you 0.91. The added Part 2 data had two cases over 288 patient-years, or 0.69. One patient had a platelet count over 900,000 at baseline and was later diagnosed with a blood-cell cancer. The other was diagnosed with prostate cancer after roughly three months on the drug. Investigators assessed both as unrelated. Then you get to the full 50 mg dataset and the rate is 0.64. If your case depends on the smaller slice, explain why the rest of the exposure should count for less rather than ignoring it because it's inconvenient to your short report credibility. sec.gov/Archives/edgar/data/…
Scorpion’s UVA experiment is a lab measurement of light absorption. The public trial protocol already disclosed animal phototoxicity for obefazimod’s main breakdown product and required sun precautions and skin monitoring. The observed 50 mg skin cancer rate across Phase 2 and 3 still came in below the historical benchmark. That comparison leaves room for a rare or delayed risk, but again no evidence. It makes the sweeping cancer claim a lot harder to sell AND physicians are already screening for skin cancer risk due to OTHER STANDARD OF CARE DRUGS THAT CAUSE CANCER IN THESE PATIENTS AND CAN CONFOUND THE SKIN CANCER FINDINGS IN EXPERIMENTAL DRUG TRIALS. scorpionreports.s3.us-east-2… · cdn.clinicaltrials.gov/large… · ir.abivax.com/static-files/b…
Now explain the biopsies.
Two blinded Phase 3 trials randomized 1,275 patients. At 50 mg, eight-week remission was 21.7% vs 2.5% on placebo in one trial and 19.8% vs 6.3% in the other. The 25 mg dose missed the main endpoint in the second trial. The 50 mg dose hit it in both. sec.gov/Archives/edgar/data/…
Then 580 patients who had responded to obefazimod were randomized again. After 44 more weeks, 51% were in remission on either dose versus 10% after switching to placebo. A normal-looking colon on scope? 42% at 25 mg, 48% at 50 mg, 10% on placebo. Improvement confirmed by both scope and biopsy? 50%, 57%, 10%. If widespread gut-cell damage is your explanation for how this drug works, explain why the tissue looked healthier under the microscope. abivax.com/wp-content/upload…
And the evidence goes back further. All three doses improved the main disease-activity score in the 254-patient Phase 2b trial. In the open-label follow-up, 114 of 217 were in remission at two years, with missing results counted as failures. In a separate, selected group that stepped down to 25 mg, 88 of 130 were in remission three years later. That’s a substantial record of follow-up on top of the three blinded Phase 3 trials. sciencedirect.com/science/ar… · academic.oup.com/ecco-jcc/ar… · sec.gov/Archives/edgar/data/…
“Foreign trials” is doing a lot of work here.
The Phase 3 trials enrolled across 36 countries. Eastern Europe accounted for 38% of enrollment. In Western Europe, 50 mg remission was 19.0% vs 5.6% on placebo. In a smaller exploratory North American group, it was 8 of 62 vs 0 of 36, with scopes also favoring treatment. The protocol called for independent central readers who were blinded to treatment and visit order. If Scorpion has evidence of misconduct, show the sites, the records and what happens to the results when those sites are removed. sec.gov/Archives/edgar/data/… · academic.oup.com/ecco-jcc/ar… · abivax.com/wp-content/upload… · cdn.clinicaltrials.gov/large…
The “150-fold” experiment used zero cells. ZERO CELLS. Why are we relying on experiments that don't even include living cells when we have thousands of patient years worth of safety data?
Scorpion measured about one-fifth of the nominal drug concentration in a cell-free reconstruction, then applied that result to cell data from 2015 to get the 150-fold headline. That raises a question about an old assay. The DDT comparison is based on fat solubility. In people given 50 mg, the parent drug’s plasma half-life was about one hour and its main breakdown product’s was about four days. If the claim is dangerous accumulation in human tissue, show the tissue exposure. scorpionreports.s3.us-east-2… · scorpionreports.s3.us-east-2… · journals.asm.org/doi/10.1128…
And the supposedly fictitious biology was measured in patients. Both doses raised miR-124 in blood and colon tissue versus placebo in Phase 3, following the same finding in Phase 2. The Phase 3 analysis included 673 paired sigmoid biopsies, alongside paired rectal biopsies and blood samples. Scorpion can question the old binding assay. It still has to deal with the separate structural work and the biological change measured in actual patients. scorpionreports.s3.us-east-2… · academic.oup.com/ecco-jcc/ar… · pmc.ncbi.nlm.nih.gov/article… · abivax.com/wp-content/upload…
The cancer cases deserved a serious look in June. We did the math then, and the expanded 50 mg data landed right within our estimates of background cancer rates in ulcerative colitis patients. Scorpion has a set of lab hypotheses and a fraud headline and completely ignores the fact the drug has show ZERO EVIDENCE OF ANYTHING THEY CLAIM IN THOUSANDS OF HUMAN BEINGS AND THEREFORE IS MOST LIKELY COMPLETELY WRONG.
Abivax has two positive 50 mg induction trials, a positive randomized maintenance trial at both doses, and biopsies that show the colon getting healthier. If you want to overturn that record, bring CLINICAL EVIDENCE that can explain it.
$ABVX As a follow-up to a few posts that I saw regarding the perceived elevated rates of NMSC and malignancies in the 50 mg arm specifically in the phase 3:
A few thoughts:
1) The phase 3 50 mg dose is actually a small minority of the patient years of safety data acquired -- the much larger dataset for that dose comes from the phase 2b long-term open label follow-up, which can be reasonably pooled with the phase 3 results given the same dose and detection protocols (Note, we have seen some analyses that pool 25 mg and 50 mg arms. We would NOT recommend doing this as it is not fair to claim that the risk of developing cancer in the 25 mg arm is known to be the same as the 50 mg arm). Pooling 50 mg phase 2b and 50 mg phase 3 data sets yields a much lower rate of events across the board. (I suspect it was just a bit of bad luck on the smaller phase 3 dataset for the 50 mg dose in isolation, see below chart for what we've been working off of after integrating these phase 2 data -- note there are some assumptions that go into this but the variability should be pretty de minimis);
2) Two ways things generally cause cancer: DNA damage from some oxidative/radiation/something else source that damages DNA or inhibits DNA repair mechanisms at their core OR substantial or highly targeted immunosuppression. Because both of these events are total exposure related, typically events accelerate over time. The phase 2 had the much longer follow-up with fewer patients whereas the phase 3 had more patients followed up for less time. The phase 2 had a very low number of events, and the phase 3 50mg dose was the only arm that had an elevated set. A priori, if the drug was a carcinogen, we would have expected the opposite: that the phase 2 would have a higher incidence/100 PY than the phase 3 given the individual patient exposures on a cumulative basis to such carcinogens are much higher in the phase 2 than the phase 3 in addition to the idea that there is a delay between when the carcinogen can cause the malignancy to when it can be detected (and T=0 is always the first instance in which that timer could start). Also, if the drug was as immunosuppressive as would be needed to cause cancer, you would expect to see a boatload of opportunistic infection before you'd see the cancer signal -- we see none.;
3) Pre-clinical testing confirmed that the drug is actually an anti-proliferative -- we would have expected the drug to be protective against tumor growth, not stimulating it;
4) No consistency or clustering for any cancer type at any time point;
5) NMSC carries a much different (lower) risk profile than other types of malignancies since they are caught very easily and have a low rate of metastases, and are seen at a massively disproportionately high case numbers relative to other types of malignancies (also included in the bottom table following pooling of the 50 mg arm), so FDA is less concerned about it than non-NMSC;
6) To warrant a black box, the FDA usually requires, at a minimum, consistency of preclinical and/or striking clinical datapoints such that careful consideration must be made to determine if the benefit/risk profile inverts in a subset of all patients that may receive the drug. In this case, we not only have completely disparate and conflicting datapoints, but we even have one data point relating to the MoA and pre-clinical data findings that suggest the drug should have the opposite effect. In addition, black box decisions are not made in isolation. They are heavily debated back and forth between the company, internally, require a lot of internal consensus on establishing causal link, and are not made in a vacuum to unmet need and efficacy;
7) UC patients have an elevated rate of inflammation (by definition) and, in turn, elevated rates of cancer compared to healthy individuals (~+.5 events/100PY vs non-UC). Obefazimod is now a proven highly effective therapy that leads to robust endoscopic remissions and attenuation of much of this inflammatory effect. I would hypothesize if you ran a large enough study and followed patients for long enough, you would find that there would be a cancer benefit from the drug secondary to the disease control that it would afford. The weight of this potential benefit (which makes sense given the pathophysiology) must be considered against the risk of the agent itself causing cancer (for which we have no reason to believe it actually should cause cancer).
Teldar Paper retweeted
$AMZN owns more Anthropic shares than all Anthropic's founders combined
Teldar Paper retweeted
$CGON quick thoughts before I catch a flight. New PT $150
HR 0.32!!!! Clean safety
LG was 3/4 events so HG alone could never drag the pooled HR anywhere near here. A 0.32 means it works in LG too.
$cgon now is:
• Only adjuvant drug for ~50K US IR pts with no approved option
• BLA for IR + HG Ta in 2Q27, plus a broader BCG unresponsive filing
• Backbone across NMIBC!
Why $150: at 0.32 creto is SOC in IR. at 0.32 and $4bn+ peak is reasonable. 3x peak sales plus ~$1bn cash is ~$150, before any M&A premium.
And it's now one of the cleanest strategic assets in onc. Own manufacturing, ANI royalty fight won, no converts, randomised IR data nobody else has.
$KOD went 50 to 80 on the day and kept going. Same setup.
Now that we’re past a potential “bad news”Friday data dump on $CGON, I’m hopeful that will see good news tomorrow morning. We’ve been waiting for so long…it’s time!
1
337
Really amazing strength and vol in $BBIO today. Quite uncharacteristic for the stock. Already traded > than it's 50-day avg volume
1
175
Teldar Paper retweeted
$MDGL Analysts question whistleblower allegations against Madrigal
Teldar Paper retweeted
$KURA The most undervalued commercial onco-play?
Late 2025 approved AML drug ziftomenib is rapidly gaining traction: Q2 sales $9.1M (+57% QoQ), and they already have the majority of new starts in r/r NPM1m AML (per Kura). IMO, investors have underestimated the once-daily dosing vs $SNDX twice-daily + potential cardiac safety edge.
The biggest upside is still frontline AML: $350-400M current US TAM vs $7B expanded TAM. Mgmt sees $3B peak sales potential. ASH (abstracts Nov 4): possible aza/ven durability, FLT3 combos & broader AML data. Earlier 96% CRc with ziftomenib + 7+3. Durability will be a key, a lot to expect for esp. updated data at ASH in dec.
Risks: J&J bleximenib (Ph3, update schedule not given) & $SNDX competition.
A great commercial play with significant upsise, and if the frontline data holds up, we are looking at 3x-10x the valuation. CEO just having bought shares twice and talked about adding also reassures the long term theses.
Next catalyst: earnings and ASH abstracts both in two weeks.
Do your own DD.
Big line in the sand on $LQDA drawn with a big block of April 35 Puts being SOLD to open
Teldar Paper retweeted
$TGTX Prakhar - Positioning seems long into earnings, as investors noted to us that third-party data sources, such as claims data, suggest a strong Q3
You have to hand it to $TGTX. While there has been blood all over the street, TG has been very stable. Azer-Cel coming on the 23rd and perhaps that coincides with a better overall mkt, and an upswing on the XBI.
$TGTX Feb 80 PUTS sold to open. 👀
That's a nice bullish move that captures JPM
1
5
604












